Morgan Stanley says buy Teva because its turnaround is still in the ‘early innings’

Investing News

Investors should buy shares of Teva Pharmaceutical Industries as the company’s turnaround picks up steam, Morgan Stanley analyst David Risinger said Monday.

Risinger upgraded the stock to overweight from equal weight. He also hiked his price target on the stock to $27 a share, implying a 19.5 percent upside from the stock’s close on Friday. Teva traded around $22.75 on Monday.

“We expect continued improvement in Teva’s financials and investor perception,” Risinger said in a note to clients. “Recall that Teva is just a year into its 3-year restructuring plan, and 25% EBITDA upside in 3Q gave us greater confidence that Teva can deliver additional cost cutting and earnings surprise in coming years.”

Products You May Like

Articles You May Like

Cramer’s 3 cardinal rules for investing during a bear market
3 Overpriced Semiconductor Stocks Due for a Fall
Cramer’s lightning round: Don’t buy shares of Target until after it reports
Trade of the Day: Dabble in Beaten-Up Schlumberger Stock
Cramer’s lightning round: Dropbox’s stock is a buy even after the tech sell-off

Leave a Reply

Your email address will not be published. Required fields are marked *